It is a link for moving within the page.

  1. HOME
  2. Pharmaceutical Business
  3. Pharmaceutical Business Products

Pharmaceutical Business Products

By choosing to tackle unaddressed medical needs, we put ourselves on the path to creating new therapeutic approaches and unprecedented drugs. Our researchers are committed to continuing to take the road less travelled, to develop solutions that only we can create.

Otsuka prescription drugs on the global market

For a better understanding of how to use our drugs correctly

Antipsychotic

REXULTI / RXULTI*
*brand name in EU

REXULTI / RXULTI was discovered by Otsuka and is being co-developed and co-marketed, where approved, by Otsuka and Lundbeck for the treatment of schizophrenia. In the U.S. it is also co-marketed as an adjunctive treatment for major depressive disorder. In 2018 it was launched in Japan, and is now sold in approximately 60 countries worldwide. It acts as an SDAM(serotonin-dopamine activity modulator).

The information in the product description is current as of August 2021.

Antipsychotic

ABILIFY Maintena, a prolonged release aquaeous suspension for intramuscular injection

ABILIFY Maintena is administered by injection once monthly. It is a long-acting formulation of the antipsychotic ABILIFY (aripiprazole). In 2013, ABILIFY Maintena was launched in the U.S. with an indication for schizophrenia and subsequently has become available in over 50 countries. In 2017 the product was approved for use in treatment of bipolar I disorder in the U.S. and Canada. In Japan, it was launched in 2015 for the treatment of schizophrenia and approved for the additional indication of bipolar I disorder in 2020.

The information in the product description is current as of August 2021.

Antipsychotic

ABILIFY

ABILIFY is an antipsychotic with the world's first dopamine D2 receptor partial agonist action, which was discovered by Otsuka. In Japan it was launched in 2006 for the treatment of schizophrenia and in 2012 obtained an additional indication for improvement of manic symptoms of bipolar disorder.

The information in the product description is current as of August 2021.

Pseudobulbar Affect (PBA) agent

NUEDEXTA (sold in the U.S.)

NUEDEXTA is the world's first and only approved treatment for pseudobulbar affect (PBA). It is a combination of dextromethorphan hydrobromide, which acts on the central nervous system, and quinidine sulfate, which inhibits metabolism in order to increase the effective blood concentration of dextromethorphan. It is marketed by Avanir Pharmaceuticals, an affiliate in the U.S.

The information in the product description is current as of August 2021.

Dopaminergic antiparkinsonian agent
Restless legs syndrome agent

Neupro Patch

Neupro Patch is the world's only once-daily transdermal dopamine agonist. In 2002 Otsuka obtained development and marketing rights in Japan from the Belgian company UCB. In Japan, it has been marketed since 2013.

The information in the product description is current as of August 2021.

A therapeutic drug treatment to reduce alcohol consumption

Selincro

Selincro, the first dual-acting opioid system modulator in Japan, acts on the brain's motivational system, which is dysregulated in patients with alcohol dependence. In 2013 Otsuka formed an agreement with Lundbeck on the development and commercialization in Japan of Lundbeck's Selinclo. It was launched in 2019 by Otsuka.

The information in the product description is current as of August 2021.

Anti-CGRP monoclonal antibody

AJOVY

AJOVY, owned by Teva Pharmaceutical Industries, Ltd., is a subcutaneous injection of an anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. CGRP is thought to play an important role in migraine attacks. AJOVY targets the CGRP ligand, inhibiting its binding to the CGRP receptor. In 2017 Otsuka obtained development and marketing rights in Japan, and it has been marketed since 2021.

The information in the product description is current as of August 2021.

<Oncology>
Anticancer agent
(tyrosine kinase inhibitor)

ICLUSIG

ICLUSIG, discovered by Ariad (acquired by Takeda in 2017), an oral tyrosine kinase inhibitor, targets BCR-ABL, an abnormal kinase expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ICLUSIG was launched in Japan in 2016.

The information in the product description is current as of August 2021.

Conditioning agent for hematopoietic stem cell transplantation

Busulfex

Busulfex is a conditioning agent prior to bone marrow transplantation in blood cancer. It has been accepted globally as a standard treatment to support medical transplantation.

The information in the product description is current as of August 2021.

<Cardiovascular and Renal areas>
V2-receptor antagonist

Samsca / JINARC* / JYNARQUE**

brand name outside Japan for ADPKD indication (**brand name in U.S.)

Samsca is an Otsuka-discovered aquaretic with a novel mechanism of action that promotes excretion from the body of water only without affecting the excretion of electrolytes. It does this by inhibiting the antidiuretic hormone vasopressin. In Japan, it was approved for edema from heart failure (accumulation of fluid) in 2010 and edema for cirrhotic patients in 2013. In 2014 Samsca was approved in Japan as the first-in-the-world treatment of autosomal dominant polycystic kidney disease (ADPKD), and additional approvals have been received in geographies including North America and the EU member states. Currently, Samsca / JINARC / JYNARQUE is approved for several indications in over 40 countries.

The information in the product description is current as of August 2021.

Antiplatelet agent

Pletaal

Pletaal, discovered by Otsuka, inhibits platelet aggregation and has peripheral vasodilator effects. In Japan it was launched in 1988 for the treatment of symptoms associated with chronic arterial obstruction and was also approved in 2003 for prevention of recurrent cerebral infarction. In 2010, Pletaal OD tablets were released in Japan.

The information in the product description is current as of August 2021.

<Gastrointestinal>
Anti-gastritis and anti-gastric ulcer agent

Mucosta

Otsuka-discovered Mucosta has an action that protects the gastric mucosa in addition to suppressing free radicals and inflammation in the stomach. It was launched in Japan in 1990 and is now sold in multiple countries. It is widely used as a drug to control gastric mucosa injury triggered by various causes such as use of painkillers and the effects of Helicobacter pylori.

The information in the product description is current as of August 2021.

Antituberculosis drug

DELTYBA

DELTYBA, discovered by Otsuka, is one of the first new anti-tuberculosis (TB) agents in nearly 50 years. It has a new mechanism of action with antimicrobial effect by inhibition of the production of mycolic acids, which form the cell wall of TB bacteria. As a treatment for multidrug-resistant TB, DELTYBA was approved in Europe in 2014. In Japan, it was also launched in 2014. In 2015 it was listed in the WHO Essential Medicines List. Currently, DELTYBA is available in over 110 countries.

The information in the product description is current as of August 2021.

<Ophthalmology>
Therapeutic agent for dry eye

Mucosta ophthalmic suspension

Mucosta ophthalmic suspension is a novel dry eye treatment with action that repairs corneal and conjunctival damage by promoting the production of mucin. It was launched in Japan in 2012 as a disposable, unit-dose formulation.

The information in the product description is current as of August 2021.

Antiglaucoma and anti-intraocular hypertension drug

Mikeluna combination ophthalmic solution

Mikeluna combination ophthalmic solution is an once-daily eye drop containing a combination of the Otsuka-developed β-blocker cartelol hydrochloride (Mikelan LA) and the prostaglandin analogue latanoprost. It launched in Japan in 2017.

The information in the product description is current as of August 2021.

13C-Urea breath agent for diagnosis of H. pylori infection

UBIT tablet

UBIT, discovered by Otsuka, is a diagnostic agent that measures 13C-Urea in the breath to detect the presence of Helicobacter pylori in the stomach.

The information in the product description is current as of August 2021.

The images of Otsuka Pharmaceutical products on this page are solely for illustration purposes and in no way are intended as recommendations for their use, an assessment that must be made exclusively in consultation with a physician.

The use and the contents of this website are governed under the laws of Japan.